Merry Christmas and a Happy New Year
Now 2018 is almost over and Christmas and the turn of the year are just around the corner. MS-DocBlog will be going into its fifth year in 2019 and I am pretty sure that there
Continue readingNow 2018 is almost over and Christmas and the turn of the year are just around the corner. MS-DocBlog will be going into its fifth year in 2019 and I am pretty sure that there
Continue readingThis is a question that patients often ask. They understand that they need a specific MS medication, but often there is a desire to do something additional – on their own initiative and under their
Continue readingAfter the extraordinary summer of 2018, the autumn and winter season inevitably begins, and accordingly, the risk of infectious and cold diseases also increases. In particular, however, the time also begins again when the risk
Continue readingThis phenomenon is currently being discussed in both the print media and various political magazines on television. Just recently, there was a report on ARD that can still be accessed in the media library (https://www.tagesschau.de/inland/fakescience-101.html).
Continue readingWhat is the correct therapy strategy for MS? This discussion was also in focus at this year’s ECTRIMS Meeting. Given the significant pathological changes and their associated effects on brain function, which are already present
Continue readingThe role of environmental factors in the development and progression of multiple sclerosis is always of particular interest to patients. The scientific findings on this complex of topics are often the starting point for alternative
Continue readingORATORIO is the first study that was able to show a significant influence on primary chronic progressive MS by an MS drug. The effects are not overwhelming, but the antibody Ocrelizumab is nevertheless the first
Continue readingFor the 34th time, the ECTRIMS (European Committee for Treatment and Research in MS) Congress is taking place in Berlin these days. This congress is the largest meeting of its kind – over the next
Continue readingTysabri® (active ingredient Natalizumab) is a highly effective medication, but it has the significant problem of PML risk – you have already read this statement here quite often. Despite this serious side effect, I advocate
Continue readingDisruptions in the motor system are common in MS – they lead to muscle weakness of the limbs and thus to restrictions in mobility. Since MS is a disease that exclusively affects the central nervous
Continue readingUnsere Website verwendet Cookies und sammelt dabei Informationen über Ihren Besuch, um unsere Website zu verbessern (durch Analyse), Ihnen Social Media-Inhalte und relevante Werbung anzuzeigen. Weitere Informationen finden Sie auf unserer Seite . Sie können zustimmen, indem Sie auf die Schaltfläche "Akzeptieren" klicken.
Cookie-Einstellungen
Unten können Sie auswählen, welche Art von Cookies Sie auf dieser Website zulassen. Klicken Sie auf die Schaltfläche "Cookie-Einstellungen speichern", um Ihre Auswahl zu übernehmen.
Dieser Inhalt ist gesperrt. Akzeptieren Sie Cookies in der Kategorie '%CC%', um diesen Inhalt anzuzeigen.